ClinicalTrials.gg
Not yet recruitingNCT07481474Updated Jul 15, 2026

Pilot and Feasibility Study of Anti-CD14 for the Treatment of Knee Osteoarthritis

A Phase 1 interventional study of Atibuclimab and saline placebo in Knee Osteoarthritis (Knee OA), sponsored by VA Office of Research and Development. Not yet recruiting at 1 site in United States. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by VA Office of Research and Development · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Osteoarthritis, Knee by VA Office of Research and Development — 7 open to participants now, 8 under way, 2 of them phase 3. Osteoarthritis, Knee · VA Office of Research and Development.

Planned enrollment
10th of 16
40 · median 85
Started
2027
with 1 other
Phase 1
Only one
of the 17
Registered
14th of 17
by date

Among the 17 studies in Osteoarthritis, Knee by VA Office of Research and Development, this one is the 10th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2027, is the only one in phase 1, and was the 14th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

7 of the 17 studies in Osteoarthritis, Knee by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Osteoarthritis, Knee by VA Office of Research and Development, or all of them as a file.
02

Study summary

Knee osteoarthritis (KOA) is a leading cause of chronic pain and disability among Veterans, which contributes significantly to reduced mobility, impaired quality of life, and increased health care utilization. First-line therapies, including non-steroidal anti-inflammatory drugs, physical therapy, and intra-articular corticosteroids, provide modest and short-term relief, while being associated with other side effects (i.e., potential for hastened cartilage loss) and no disease-modifying potential. Total knee arthroplasty, although effective, is not suitable for all patients and carries surgical risks. There is an unmet need for effective, durable, and locally-targeted therapies that can alleviate pain and improve function. The development of new therapies for this condition is thus a priority for the VA.

While the therapy has been used in humans in other contexts, to date there are no data on the safety, feasibility, and potential efficacy IC14 administration in patients with KOA. A small-scale, Phase I pilot and feasibility trial is therefore critical to inform the design and implementation of larger, definitive studies. Specifically, preliminary data are needed to (1) determine the appropriate inclusion/exclusion criteria, (2) solidify the study design and study processes,(3) assess patient tolerance and acceptability of i.a. mAb infusion for KOA, (4) evaluate safety profiles of the localized biologic intervention. Participants will be randomized into one of two arms, (a placebo arm, and active atibuclimab arm (2 mg/kg)) and will be followed to evaluate the safety and feasibility of this treatment.

Read the detailed description

In recent years, pain in osteoarthritis has been tied to inflammation in the joint. For example, Philpott et al. found that, among 258 patients with KOA, moderate to severe synovitis on ultrasound was associated with a 2- to 4-fold increase in the risk of constant and intermittent pain. A prior study in 535 patients from the Multicenter Osteoarthritis Study (MOST) cohort found that the presence of synovitis on contrast-enhanced magnetic resonance imaging (MRI) was associated with a 9-fold increase in the risk of pain. Supporting these cross-sectional associations is the observation that corticosteroid injections, the use of which aims to reduce inflammation, have been a mainstay of treatment for years, though studies estimating these benefits are heterogeneous and suggest only modest effects. In addition to contributing to pain, synovitis is likely to contribute to the deterioration in joint structures including the progression of cartilage loss. For example, a recent study from the Osteoarthritis Initiative demonstrated that sustained synovitis on MRI was associated with more rapid structural progression over 4 years.

Despite evidence that synovitis plays a role in the symptoms and progression of the disease, to date, highly effective therapies to reduce pain in osteoarthritis by reducing synovitis have not been developed. This may be, in part, due to the complex nature of osteoarthritis pain as well as the lack of strong pathophysiologic rationale for prior therapies. For example, a number of trials evaluated the benefit of blocking Interleukin(IL)-1, with heterogeneous results suggesting small benefits.

CD14 is a pattern-recognition co-receptor of the innate immune response that plays a critical role in mediating inflammatory responses to damage-associated molecular patterns (DAMPs) present in osteoarthritic joints. In KOA, receptors like CD14 contribute to DAMP-activation of synovial macrophages which drive chronic low-grade inflammation through the release of pro-inflammatory cytokines, such as IL-1 and TNF- . These cytokines in turn sensitize nociceptors contributing to pain, and promote chondrocyte production of degradative enzymes accelerating joint degeneration. By blocking CD14, it may be possible to reduce macrophage activation and downstream inflammatory cascades within the knee, thus reducing symptoms and potentially affecting structural progression. Indeed, the investigators' published data in the murine destabilization of the medial meniscus (DMM) OA model suggests that deficiency of CD14 leads to reduced synovial cytokine expression after injury, mitigates development of pain-related behavior, and reduces cartilage loss. Thus, targeting CD14 represents a novel, mechanism-based approach to modulate synovial inflammation, potentially offering symptom relief with fewer side effects compared to traditional therapies. Fortunately, a neutralizing mAb against human CD14 (IC14) already exists and has extensive pre-clinical and in-human safety data from prior work in other conditions.

This trial would represent the first human study of this novel injectable therapeutic agent. The goal of this 2-year study is to establish feasibility and initial safety with the goal of informing the design of a Merit-funded multi-site Phase II study to establish biologic efficacy and evaluate safety within the VA network.

The central study team includes experts in clinical epidemiology and clinical trials, rehabilitation medicine, osteoarthritis, and rheumatology at the VA. Joshua Baker is an Associate Professor of Medicine and Epidemiology at the Hospital of the University of Pennsylvania and the CMCVAMC. He is a VA-funded investigator with an interest in obesity, muscle loss, physical functioning, and long-term outcomes in patients with common forms of arthritis. He is the Clinical Core 3 Co-Leader of the CReATE Motion Center, the Co-Director of the local Network of Dedicated Enrollment Sites (NODES) program, and Director of the Clinical Research Center at the CMCVAMC. He has served as the national PI for 2 RDT-funded trials including the MOVE-OK trial and the ongoing ReAKTIV trial. He has also served as a local site investigator (LSI) for several VA-funded clinical trials.

The CReATE Motion center was recently funded by VA RDT with the goal of promoting the more rapid translation of highly promising new therapeutics that have the potential to improve the lives of Veterans with osteoarthritis. Dr. Baker is the Director of the Clinical Core, which can provide project manager and research coordinator effort for center-related studies. In addition to this support, the center provides institutional knowledge and experience with clinical studies in KOA, including the ability to generate recruitment lists, organize off-site testing (e.g. MRI), contribution to screening and recruitment, and oversight of data integrity. These resources will be leveraged as part of this protocol.

The study is a randomized trial with 2 arms (40 patients, randomized 3:1) with a 16-week follow-up. Patient-reported outcomes will be assessed at 2-week intervals and safety as well as physical functioning assessed and blood draws performed at in-person visits at month 1 and 3. Participants may also have synovial fluid removed from their knee at in-person visits. Participants will undergo a non-contrast MRI scan before randomization and administration of the study drug or placebo. They will also receive another MRI at 3 months. The investigators aim to randomize 40 Veterans within 18 months.

In this currently proposed study, the dose will be consistent with prior studies (2 mg/kg IV).

Participants will be monitored by study investigators and an independent data safety monitoring officer (DSMO) will be identified. The study will include regular clinical assessments, with moderate to severe events resulting in a pause to further randomizations after discussion with the IRB. A Data and Safety Monitoring Plan (DSMP) will be generated and approved by the DSMO. Standard procedures for medical emergencies will be followed. All adverse events will be reported to the IRB and applicable regulatory bodies in accordance with federal regulations.

There is no guarantee of direct benefit to participants. However, participants may benefit from increased clinical monitoring. The knowledge gained from this trial may benefit future patients by improving the understanding of CD14-targeted therapies and their safety profiles.

03

Conditions studied

  • Knee Osteoarthritis (Knee OA)
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ACR Classification Criteria for Knee Osteoarthritis
  • Pain >=5 on Visual Analogue Scale
  • Kelgren-Lawrence Grade >1
  • Joint Effusion on Exam
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Serious or hospitalized infection in last 1 year
  • Poorly controlled crystal arthritis in last 6 months
  • Pain Pressure Threshold (PPT) testing \<=3
  • History of diagnosed fibromyalgia
  • Receipt of in affected knee within 3 months
  • Receipt of visco-supplementation or other intra-articular therapy (other than corticosteroid) within 6 months
  • Ongoing participation in another interventional study
  • Inability to ambulate without assistive device
  • Pregnancy or Lactation
  • History of knee arthroplasty in either knee
  • Symptomatic heart failure
  • \<45
  • Class III obesity (>40 kg/m2)
  • Recent active (chemotherapy, radiation, or surgery within 3 months)
  • Poorly controlled diabetes (A1c>8%)
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Atibuclimab 20 mg/kg

    IV infusion of atibuclimab

    Biological: Atibuclimab

  • Placebo comparator
    Placebo (saline only)

    placebo infusion of saline

    Other: saline placebo

Interventions

  • BiologicalAtibuclimab

    IV injection of Atibuclimab

  • Othersaline placebo

    IV infusion of saline

06

What researchers measure

Primary outcomes

  1. Rates of screening and randomization

    The number of randomized participants relative to the number screened. The screening protocol will be considered feasible if 1/2 of screened patients are eligible to be randomized.

    Time frame: 2 years

Secondary outcomes

  1. Rates of study completion

    Rates of completion of study procedures. The design will be considered to be feasible if 90% complete 4-month follow-up from randomization.

    Time frame: 2 years

  2. Rates of serious adverse events

    The study will quantify emergency room visits, hospitalizations, and life-threatening events and determine relatedness. Rates will be quantified over 4 months of follow-up and evaluated descriptively by group.

    Time frame: 4 months

07

Study locations

1 site
  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
    Philadelphia, Pennsylvania 19104-4551, United States
    • Joshua F Baker, MD MSCE · ContactJoshua.Baker@va.gov · 215-823-5800
    • Joshua F. Baker, MD MSCE · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Sharing of data would require approvals from the VA IRB.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jun 2027, 5 months later.

Of 61 phase 1 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 18, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07481474
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Jul 15, 2026

Study contacts

Joshua F Baker, MD MSCE
Contact
Joshua.Baker@va.gov
(215) 823-5800
Criswell Lavery, MPH
Contact
criswell.lavery@va.gov
(215) 823-4630
Joshua F. Baker, MD MSCE
principal investigator · Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atibuclimab

Start the discussion